# Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

> **NCT02633800** · PHASE2 · TERMINATED · sponsor: **Daiichi Sankyo** · enrollment: 87 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Patritumab
- **DRUG:** Cetuximab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02633800
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-22
- **Primary completion:** 2018-01-11
- **Final completion:** 2018-02-21
- **Target enrollment:** 87 (ACTUAL)
- **Why stopped:** Trial was terminated by sponsor due to lack of efficacy.
- **Last updated:** 2019-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633800, "Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02633800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*